Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04273815
- Locations
- 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT04236362
- Locations
- 🇨🇳
The General Hospital of the People's Liberation Army, Beijing, Beijing, China
🇨🇳The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳Cancer Hospital of Chongqing University, Chongqing, Chongqing, China
A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 738
- Registration Number
- NCT04234607
- Locations
- 🇨🇳
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
A Study of Anlotinib in Subjects With Advanced Malignancy
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT04216082
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04207463
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
🇨🇳Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Jilin, China
A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT04203719
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04180150
- Locations
- 🇨🇳
The second affiliated hospital of chongqing medical university, Chongqing, Chongqing, China
🇨🇳The first hospital of Jilin University, Changchun, Jinlin, China
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04144855
- Locations
- 🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳Yongsheng, Chendu, Sichuan, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant Tumors
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04128085
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 184
- Registration Number
- NCT04073550
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China